Access
To read this story in full you will need to login or make a payment (see right).
Commentary
Nature 453, 851-852 (12 June 2008) | doi:10.1038/453851a; Published online 11 June 2008
Open Innovation Challenges
-
Methods of Modeling Adaptation in Populations
The analysis of adaptation with a population is a frequently encountered computational modeling scen...
-
Single-cell Analysis Platform
This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is...
- More Challenges
- Powered by:
nature jobs
Postdoctoral Position
- Fox Chase Cancer Center
- Philadelphia, Pennsylvania, United States, 19111
Head, Medical Writing
- Cactus Global
- Mumbai 400053 India
Follow the leader
Kaori Tsuji1 & Kiichiro Tsutani2
- Kaori Tsuji is at the Health Care Science Institute, Akasaka NOA 5F, 3-2-12 Akasaka, Minato-ku, Tokyo 107-0052, Japan.
- Kiichiro Tsutani is at the University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.
Abstract
If Japan is to become a front-runner in pharmaceutical development, it must not only speed up its approval of new drugs, but also enhance its own research capabilities, argue Kaori Tsuji and Kiichiro Tsutani.
How long should a therapy take to journey from lab bench to bedside? The obvious need to prove the safety and efficacy of an investigational therapeutic product has notoriously led to delays that that can be aggravating for both drug developers and patients.
To read this story in full you will need to login or make a payment (see right).
